<?xml version='1.0' encoding='utf-8'?>
<document id="31863284"><sentence text="The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants."><entity charOffset="14-22" id="DDI-PubMed.31863284.s1.e0" text="Rifampin" /><entity charOffset="61-71" id="DDI-PubMed.31863284.s1.e1" text="Lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31863284.s1.e0" e2="DDI-PubMed.31863284.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31863284.s1.e0" e2="DDI-PubMed.31863284.s1.e1" /></sentence><sentence text="Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer; cytochrome P450 (CYP) 3A plays an important role in the metabolism of lorlatinib"><entity charOffset="0-10" id="DDI-PubMed.31863284.s2.e0" text="Lorlatinib" /><entity charOffset="33-41" id="DDI-PubMed.31863284.s2.e1" text="tyrosine" /><entity charOffset="240-250" id="DDI-PubMed.31863284.s2.e2" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31863284.s2.e0" e2="DDI-PubMed.31863284.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31863284.s2.e0" e2="DDI-PubMed.31863284.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s2.e0" e2="DDI-PubMed.31863284.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31863284.s2.e1" e2="DDI-PubMed.31863284.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s2.e1" e2="DDI-PubMed.31863284.s2.e2" /></sentence><sentence text="" /><sentence text="This phase 1, open-label, two-period, crossover study estimated the effect of oral rifampin (a strong CYP3A inducer) on the pharmacokinetics and safety of oral lorlatinib (NCT02804399)"><entity charOffset="83-91" id="DDI-PubMed.31863284.s4.e0" text="rifampin" /><entity charOffset="160-170" id="DDI-PubMed.31863284.s4.e1" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31863284.s4.e0" e2="DDI-PubMed.31863284.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31863284.s4.e0" e2="DDI-PubMed.31863284.s4.e1" /></sentence><sentence text=" Healthy participants received single-dose lorlatinib 100 mg in period 1 followed by rifampin 600 mg/day (days 1-12) and single-dose lorlatinib 100 mg (day 8) in period 2"><entity charOffset="43-53" id="DDI-PubMed.31863284.s5.e0" text="lorlatinib" /><entity charOffset="85-93" id="DDI-PubMed.31863284.s5.e1" text="rifampin" /><entity charOffset="133-143" id="DDI-PubMed.31863284.s5.e2" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31863284.s5.e0" e2="DDI-PubMed.31863284.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31863284.s5.e0" e2="DDI-PubMed.31863284.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s5.e0" e2="DDI-PubMed.31863284.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31863284.s5.e1" e2="DDI-PubMed.31863284.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s5.e1" e2="DDI-PubMed.31863284.s5.e2" /></sentence><sentence text=" Blood samples were collected for 120 h after each dose of lorlatinib"><entity charOffset="59-69" id="DDI-PubMed.31863284.s6.e0" text="lorlatinib" /></sentence><sentence text="" /><sentence text="When a single dose of lorlatinib was administered during daily dosing with rifampin (period 2), the area under the plasma concentration-time profile extrapolated to infinity (AUCinf) and maximum plasma concentration (Cmax) of lorlatinib were 14"><entity charOffset="22-32" id="DDI-PubMed.31863284.s8.e0" text="lorlatinib" /><entity charOffset="75-83" id="DDI-PubMed.31863284.s8.e1" text="rifampin" /><entity charOffset="226-236" id="DDI-PubMed.31863284.s8.e2" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31863284.s8.e0" e2="DDI-PubMed.31863284.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31863284.s8.e0" e2="DDI-PubMed.31863284.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s8.e0" e2="DDI-PubMed.31863284.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31863284.s8.e1" e2="DDI-PubMed.31863284.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s8.e1" e2="DDI-PubMed.31863284.s8.e2" /></sentence><sentence text="74% [90% confidence interval (CI) 12" /><sentence text="78%, 17" /><sentence text="01%] and 23" /><sentence text="88% (90% CI 21" /><sentence text="58%, 26" /><sentence text="43%), respectively, of those in period 1 (lorlatinib alone)" /><sentence text=" A single dose of lorlatinib was well tolerated in period 1, but elevations in transaminase values were observed in all participants (grade 2-4 in 11 participants) within 1-3 days after a single dose of lorlatinib was administered with ongoing rifampin in period 2"><entity charOffset="18-28" id="DDI-PubMed.31863284.s15.e0" text="lorlatinib" /><entity charOffset="203-213" id="DDI-PubMed.31863284.s15.e1" text="lorlatinib" /><entity charOffset="244-252" id="DDI-PubMed.31863284.s15.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.31863284.s15.e0" e2="DDI-PubMed.31863284.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31863284.s15.e0" e2="DDI-PubMed.31863284.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s15.e0" e2="DDI-PubMed.31863284.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31863284.s15.e1" e2="DDI-PubMed.31863284.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s15.e1" e2="DDI-PubMed.31863284.s15.e2" /></sentence><sentence text=" Rifampin dosing was therefore halted"><entity charOffset="1-9" id="DDI-PubMed.31863284.s16.e0" text="Rifampin" /></sentence><sentence text=" Transaminase levels subsequently returned to normal (median time to recovery: 15 days)" /><sentence text=" No elevations in bilirubin were observed"><entity charOffset="18-27" id="DDI-PubMed.31863284.s18.e0" text="bilirubin" /></sentence><sentence text="" /><sentence text="The addition of a single dose of lorlatinib to daily dosing with rifampin significantly reduced lorlatinib plasma exposure relative to a single dose of lorlatinib administered alone and was associated with severe but self-limiting transaminase elevations in all healthy participants"><entity charOffset="33-43" id="DDI-PubMed.31863284.s20.e0" text="lorlatinib" /><entity charOffset="65-73" id="DDI-PubMed.31863284.s20.e1" text="rifampin" /><entity charOffset="96-106" id="DDI-PubMed.31863284.s20.e2" text="lorlatinib" /><entity charOffset="152-162" id="DDI-PubMed.31863284.s20.e3" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e0" e2="DDI-PubMed.31863284.s20.e0" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e0" e2="DDI-PubMed.31863284.s20.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e0" e2="DDI-PubMed.31863284.s20.e2" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e0" e2="DDI-PubMed.31863284.s20.e3" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e1" e2="DDI-PubMed.31863284.s20.e1" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e1" e2="DDI-PubMed.31863284.s20.e2" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e1" e2="DDI-PubMed.31863284.s20.e3" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e2" e2="DDI-PubMed.31863284.s20.e2" /><pair ddi="false" e1="DDI-PubMed.31863284.s20.e2" e2="DDI-PubMed.31863284.s20.e3" /></sentence><sentence text=" These observations support the contraindication in the product label against concomitant use of lorlatinib with all strong CYP3A inducers"><entity charOffset="97-107" id="DDI-PubMed.31863284.s21.e0" text="lorlatinib" /></sentence><sentence text="" /><sentence text="ClinicalTrials" /><sentence text="gov identifier, NCT02804399" /><sentence text="" /></document>